Q2 2027 STERIS plc Earnings Conference Call - STERIS PLC

Financial Performance:

• Total reported revenue increased 9% year-over-year to $1.6 billion for Q2 2027.
• Constant currency organic revenue growth was 8%, driven by volume and 230 basis points of pricing.
• Adjusted gross margin expanded 100 basis points to 45.3%, with 130 bps attributable to tariff refunds; underlying margins were flat due to inflation offsetting price.
• Adjusted EBIT margin rose 150 bps to 24.6%, with 130 bps of growth from tariff refunds ($20M impact).
• Adjusted net income was $286.8 million; adjusted EPS was $2.94, a 19% increase year-over-year ($2.47).
• Excluding tariff refunds, adjusted EPS grew 13%.
• Free cash flow for the first half of the year was $492.5 million, down from $527.7 million, primarily due to inventory buildup for H2 shipments.
• Total debt stood at $1.9 billion, resulting in a gross debt-to-EBITDA ratio of 1.1x.
• Capital expenditures were $76.1 million, with $125.6 million in depreciation and amortization.

Guidance and Future Outlook:

• Fiscal 2027 constant currency organic revenue guidance remains unchanged at 6% to 7%; reported revenue growth is 7% to 8%.
• Fiscal 2027 adjusted EPS guidance increased to $11.35–$11.55 (up from $11.10–$11.30), reflecting Q2 outperformance, lower interest, and $0.18 per share benefit from tariff refunds.
• No material additional tariff refunds are expected in the remainder of fiscal 2027.
• Healthcare segment growth outlook maintained at 6% to 7%.
• AST segment growth outlook lowered to 6% to 7% (previously 7% to 8%) due to maintained Q2 exit rates.
• Life Sciences segment growth outlook raised to 9% to 10% (previously 6% to 7%) based on strong H1 performance and normalized H2 expectations.
• Revenue and margin expectations for the new acquisition (Exodus Medical) are not included in current guidance and will be updated post-closing.

Business Segments and Product Lines:

• Healthcare: Constant currency organic revenue grew 7%; Services grew 10%, Consumables grew 10% (driven by endoscopy share gains and GI acquisition), and Capital Equipment grew 4%. Backlog reached $456 million. Margins declined 110 bps to 24% due to inflation and R&D acceleration.
• AST (Applied Sterilization Technologies): Constant currency organic revenue grew 5%; Services grew 6% constant currency. Margins decreased 60 bps to 44.7% due to inflation and depreciation.
• Life Sciences: Constant currency organic revenue surged 18%; Capital Equipment grew 53%, Consumables grew 9%, and Services grew 5%. Margins hit a record 44.4%, up 310 bps, driven by reshoring and favorable mix.
• Acquisition: Announced agreement to acquire Exodus Medical, a surgical specialties business focusing on patient safety and single-use positioning products, expected to boost recurring revenue and OR market presence.
• Restructuring: Approved a new plan ($45M total charges, $10M cash) targeting facility realignment and product rationalization (including discontinuing a single-use urology scope); expected to generate $9M in annualized savings by fiscal 2028.

Market and Competitive Landscape:

• Healthcare procedural volumes are growing at the low end of estimates (~3%) but remain positive; no significant slowdown observed despite economic stress.
• Life Sciences benefited from "reshoring" trends and pent-up demand for capital equipment following years of underbuying.
• AST end of customer destocking observed in Q2, with October showing normalized revenue growth.
• Competition in GI: Competitor (Olympus) challenges mentioned as having minor impact on Staris's AER sales; Staris attributes growth to execution and market share gains rather than competitor issues.
• Capital equipment backlog in Healthcare is near record highs, excluding the previous supply chain crisis period.

Risks and Challenges:

• Inflation continues to pressure underlying margins, partially offset by price increases.
• Macroeconomic uncertainty regarding elective procedures, though demand remains resilient.
• Future margin improvement is constrained by the lack of additional tariff refunds and continued investment in R&D.
• Integration risks associated with the Exodus Medical acquisition.
• Potential headwinds from 340B reform rules, though no immediate CapEx slowdown is currently observed.

Management Commentary and Tone:

• Management tone was confident and positive, citing strong execution and favorable market trends.
• Emphasis placed on the "outperformance" of Life Sciences and the stability of the Healthcare portfolio despite macro noise.
• Dan Crestio (CEO) highlighted the strategic value of the Exodus acquisition in establishing a daily call point in the operating room.
• Karen Burton (CFO) provided clear differentiation between tariff-driven growth and underlying operational performance.

Analyst Questions and Answers:

• Exodus Acquisition: Confirmed as a high-margin, high-growth fit that adds clinical sales force and recurring consumables revenue; expected to be EPS accretive (3-5%) but interest costs on debt funding will be factored in.
• AST Volumes: Management confirmed utilization is high with adequate capacity; destocking has ended, and growth is expected to persist in the back half.
• Life Sciences: Attributes strong growth to a combination of reshoring, localization of manufacturing, and a large ($10M+) single customer order in H1; sees "self-driving labs" as a future opportunity but not yet materializing in orders.
• Tariffs: Total refund pool confirmed at $24M for the full year (down $3M from 2026 payments with no refund program), with no further refunds expected.
• Healthcare Consumables: Growth divergence vs. AST volumes explained by long-term equipment placements (AERs) converting to consumables and strong endoscopy procedural growth.
• Restructuring: Clarified as a multi-year strategy involving portfolio optimization and supply chain consolidation, separate from the previously announced chemistry center of excellence project.

Other Key Points:

• Share buybacks totaled $100M in Q2 ($200M YTD), with $800M remaining under authorization.
• Tariff refunds were booked at the corporate level to isolate segment performance.
• The Life Sciences segment saw a 53% surge in capital equipment revenue, the primary driver of the 18% segment growth.
• Management reiterated that the current outlook does not include the financial impact of the Exodus Medical deal.